The aim of this paper is to contribute to the challenging process of clinical decision making in the first-line treatment of advanced EGFR-mutant NSCLC by describing the three main treatment options and also by proposing all the points of view from which the scenario can be looked at, going beyond the mere results of clinical trials. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.